Vitamin D, calcium homeostasis and aging

Bone Research

Volumn 4, Issue , 2016, Pages

  Veldurthy, Vaishali ^a   Wei, Ran ^a   Oz, Leyla ^a   Dhawan, Puneet ^a   Jeon, Yong Heui ^a   Christakos, Sylvia ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLENE 19 NOR 1ALPHA 25 DIHYDROXYVITAMIN D3; ALFACALCIDOL; CALCIUM; ELDECALCITOL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

AGING; CALCIUM BALANCE; CALCIUM HOMEOSTASIS; FRACTURE; HUMAN; NONHUMAN; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

EID: 84992166495     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2016.41     Document Type: Review

References (79)

1. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol 2010; 5 (Suppl 1): S23-S30.
2. Morris HA, Need AG, Horowitz M et al. Calcium absorption in normal and osteoporotic postmenopausal women. Calcif Tissue Int 1991; 49: 240-243.
3. Ensrud KE, Duong T, Cauley JA et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med 2000; 132: 345-353.
4. Christakos S. Recent advances in our understanding of 1,25-dihydroxy Vitamin D(3) regulation of intestinal calcium absorption. Arch Biochem Biophys 2012; 523: 73-76.
5. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 2007; 45: 139-167.
6. Plum LA, De Luca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010; 9: 941-955.
7. Bikle DD, Adams J, Christakos S. Vitamin D: production, metabolism and clinical requirements//Rosen C. Primer on Metabolic Bone Diseases. Hoboken: John Wiley and Sons, 2013: 235-245.
8. Zhu J, De Luca HF. Vitamin D 25-hydroxylase - four decades of searching, are we there yet? Arch Biochem Biophys 2012; 523: 30-36.
9. Cheng JB, Motola DL, Mangelsdorf DJ et al. De-orphanization of cytochrome P450 2R1: a microsomal Vitamin D 25-hydroxylase. J Biol Chem 2003; 278: 38084-38093.
10. Zhu JG, Ochalek JT, Kaufmann M et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxy Vitamin D production in vivo. Proc Natl Acad Sci USA 2013; 110: 15650-15655.
11. Chun RF, Peercy BE, Orwoll ES et al. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol 2014; 144: 132-137.
12. Nykjaer A, Dragun D, Walther D et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) Vitamin D3. Cell 1999; 96: 507-515.
13. Kitanaka S, Takeyama K, Murayama A et al. Inactivating mutations in the 25-hydroxy Vitamin D3 1alpha-hydroxylase gene in patients with pseudo Vitamin D-deficiency rickets. N Engl J Med 1998; 338: 653-661.
14. Jones G, Prosser DE, Kaufmann M. 25-Hydroxy Vitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of Vitamin D. Arch Biochem Biophys 2012; 523: 9-18.
15. Veldurthy V, Wei R, Campbell M et al. 25-Hydroxy Vitamin D(3) 24-hydroxylase: a key regulator of 1,25(OH)(2)D(3) catabolism and calcium homeostasis. Vitam Horm 2016; 100: 137-150.
16. St-Arnaud R, Arabian A, Travers R et al. Deficient mineralization of intramembranous bone in Vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxy Vitamin D and not to the absence of 24,25-dihydroxy Vitamin D. Endocrinology 2000; 141: 2658-2666.
17. Schlingmann KP, Kaufmann M, Weber S et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011; 365: 410-421.
18. Henry HL. Regulation of Vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011; 25: 531-541.
19. Brenza HL, De Luca HF. Regulation of 25-hydroxy Vitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxy Vitamin D3. Arch Biochem Biophys 2000; 381: 143-152.
20. Hu MC, Shiizaki K, Kuro-o M et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75: 503-533.
21. Pike JW, Meyer MB. Fundamentals of Vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol 2014; 144: 5-11.
22. Christakos S, Dhawan P, Verstuyf A et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96: 365-408.
23. Amling M, Priemel M, Holzmann T et al. Rescue of the skeletal phenotype of Vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999; 140: 4982-4987.
24. Li YC, Amling M, Pirro AE et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in Vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391-4396.
25. Benn BS, Ajibade D, Porta A et al. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 2008; 149: 3196-3205.
26. Lieben L, Benn BS, Ajibade D et al. Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis. Bone 2010; 47: 301-308.
27. Cui M, Li Q, Johnson R et al. Villin promoter-mediated transgenic expression of transient receptor potential cation channel, subfamily V, member 6 (TRPV6) increases intestinal calcium absorption in wild-type and Vitamin D receptor knockout mice. J Bone Miner Res 2012; 27: 2097-2107.
28. de Groot T, Bindels RJ, Hoenderop JG. TRPV5: an ingeniously controlled calcium channel. Kidney Int 2008; 74: 1241-1246.
29. Ajibade D, Benn BS, Christakos S. Mechanism of action of 1.25 dihydroxy Vitamin D3 in intestinal calcium absorption and renal calcium transport//Holick MF. Vitamin D: Physiology, Molecular, Biological and Clinical Applications. Totowa: Humana Press, 2010: 175-187.
30. Hoenderop JG, Dardenne O, Van Abel M et al. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxy Vitamin D3 in 25-hydroxy Vitamin D3-1alpha-hydroxylase knockout mice. FASEB J 2002; 16: 1398-1406.
31. Hoenderop JG, van Leeuwen JP, van der Eerden BC et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003; 112: 1906-1914.
32. Armbrecht HJ, Zenser TV, Bruns ME et al. Effect of age on intestinal calcium absorption and adaptation to dietary calcium. Am J Physiol 1979; 236: E769-E774.
33. van Abel M, Huybers S, Hoenderop JG et al. Age-dependent alterations in Ca2+ homeostasis: role of TRPV5 and TRPV6. Am J Physiol Renal Physiol 2006; 291: F1177-F1183.
34. Brown AJ, Krits I, Armbrecht HJ. Effect of age, Vitamin D, and calcium on the regulation of rat intestinal epithelial calcium channels. Arch Biochem Biophys 2005; 437: 51-58.
35. Matkovits T, Christakos S. Variable in vivo regulation of rat Vitamin D-dependent genes (osteopontin, Ca, Mg-adenosine triphosphatase, and 25-hydroxy Vitamin D3 24-hydroxylase): implications for differing mechanisms of regulation and involvement of multiple factors. Endocrinology 1995; 136: 3971-3982.
36. Johnson JA, Beckman MJ, Pansini-Porta A et al. Age and gender effects on 1,25-dihydroxy Vitamin D3-regulated gene expression. Exp Gerontol 1995; 30: 631-643.
37. Armbrecht HJ, Zenser TV, Davis BB. Effect of age on the conversion of 25-hydroxy Vitamin D3 to 1,25-dihydroxy Vitamin D3 by kidney of rat. J Clin Invest 1980; 66: 1118-1123.
38. Pattanaungkul S, Riggs BL, Yergey AL et al. Relationship of intestinal calcium absorption to 1,25-dihydroxy Vitamin D [1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab 2000; 85: 4023-4027.
39. Ebeling PR, Sandgren ME, Di Magno EP et al. Evidence of an age-related decrease in intestinal responsiveness to Vitamin D: relationship between serum 1,25-dihydroxy Vitamin D3 and intestinal Vitamin D receptor concentrations in normal women. J Clin Endocrinol Metab 1992; 75: 176-182.
40. Horst RL, Goff JP, Reinhardt TA. Advancing age results in reduction of intestinal and bone 1,25-dihydroxy Vitamin D receptor. Endocrinology 1990; 126: 1053-1057.
41. Kinyamu HK, Gallagher JC, Prahl JM et al. Association between intestinal Vitamin D receptor, calcium absorption, and serum 1,25 dihydroxy Vitamin D in normal young and elderly women. J Bone Miner Res 1997; 12: 922-928.
42. Wood RJ, Fleet JC, Cashman K et al. Intestinal calcium absorption in the aged rat: evidence of intestinal resistance to 1,25(OH)2 Vitamin D. Endocrinology 1998; 139: 3843-3848.
43. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis 2010; 17: 302-307.
44. Reichel H, Deibert B, Schmidt-Gayk H et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-169.
45. Quarles LD. Role of FGF23 in Vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012; 318: 1040-1048.
46. Armbrecht HJ, Wongsurawat N, Zenser TV et al. Differential effects of parathyroid hormone on the renal 1,25-dihydroxy Vitamin D3 and 24,25-dihydroxy Vitamin D3 production of young and adult rats. Endocrinology 1982; 111: 1339-1344.
47. Mulroney SE, Woda C, Haramati A. Changes in renal phosphate reabsorption in the aged rat. Proc Soc Exp Biol Med 1998; 218: 62-67.
48. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.
49. Cosman F, de Beur SJ, Le Boff MS et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25: 2359-2381.
50. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
51. Cauley JA. Estrogen and bone health in men and women. Steroids 2015; 99: 11-15.
52. Cauley JA, La Croix AZ, Wu L et al. Serum 25 hydroxy Vitamin D concentrations and the risk of hip fractures: the women's health initiative. Ann Intern Med 2008; 149: 242-250.
53. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and Vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-58.
54. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of Vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.
55. Gallagher JC, Sai A, Templin T 2nd et al. Dose response to Vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med 2012; 156: 425-437.
56. Priemel M, von Domarus C, Klatte TO et al. Bone mineralization defects and Vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxy Vitamin D in 675 patients. J Bone Miner Res 2010; 25: 305-312.
57. Zhou Y, Zhao LJ, Xu X et al. DNA methylation levels of CYP2R1 and CYP24A1 predict Vitamin D response variation. J Steroid Biochem Mol Biol 2014; 144: 207-214.
58. Gallagher JC. Vitamin D and aging. Endocrinol Metab Clin North Am 2013; 42: 319-332.
59. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155-170.
60. Ralston SH, Binkley N, Boonen S et al. Randomized trial of alendronate plus Vitamin D3 versus standard care in osteoporotic postmenopausal women with Vitamin D insufficiency. Calcif Tissue Int 2011; 88: 485-494.
61. Weber K, Kaschig C, Erben RG. 1 Alpha-hydroxy Vitamin D2 and 1 alpha-hydroxy Vitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats. Bone 2004; 35: 704-710.
62. Li M, Healy DR, Simmons HA et al. Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskelet Neuronal Interact 2003; 3: 39-46.
63. Orimo H, Shiraki M, Hayashi Y et al. Effects of 1 alpha-hydroxy Vitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370-376.
64. Shikari Kushida M, Yamazaki K, Nagai K et al. H. Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy Vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, doubleblind prospective study. Endocr J 1996; 43: 211-220.
65. Hayashi Y, Fujita T, Inoue T. Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-Vitamin D3. J Bone Miner Metab 1992; 10: 50-54.
66. Nuti R, Bianchi G, Brandi ML et al. Superiority of alfacalcidol compared to Vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int 2006; 26: 445-453.
67. Kubodera N, Tsuji N, Uchiyama Y et al. A new active Vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 2003; 88: 286-289.
68. Abe M, Tsuji N, Takahashi F et al. Overview of the clinical pharmacokinetics of eldecalcitol, a new active Vitamin D3 derivative. Jpn Pharmacol Ther 2011; 39: 261-274.
69. Ritter CS, Brown AJ. Suppression of PTH by the Vitamin D analog eldecalcitol is modulated by its high affinity for the serum Vitamin D-binding protein and resistance to metabolism. J Cell Biochem 2011; 112: 1348-1352.
70. Kondo S, Takano T, Ono Y et al. Eldecalcitol reduces osteoporotic fractures by unique mechanisms. J Steroid Biochem Mol Biol 2015; 148: 232-238.
71. Harada S, Mizoguchi T, Kobayashi Y et al. Daily administration of eldecalcitol (ED-71), an active Vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2012; 27: 461-473.
72. Saito M, Grynpas MD, Burr DB et al. Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone. Bone 2015; 73: 8-15.
73. Matsumoto T, Ito M, Hayashi Y et al. A new active Vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study. Bone 2011; 49: 605-612.
74. Matsumoto T, Takano T, Saito H et al. Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol. Bonekey Rep 2014; 3: 513.
75. Sakai A, Ito M, Tomomitsu T et al. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active Vitamin D analog, compared to that of concomitant ALN, Vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int 2015; 26: 1193-1202.
76. Plum LA, Fitzpatrick LA, Ma X et al. 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int 2006; 17: 704-715.
77. Ke HZ, Qi H, Crawford DT et al. A new Vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res 2005; 20: 1742-1755.
78. De Luca HF, Bedale W, Binkley N et al. The Vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial. J Bone Miner Res 2011; 26: 538-545.
79. Zella JB, Plum LA, Plowchalk DR et al. Novel, selective Vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. Am J Nephrol 2014; 39: 476-483.